Foundation Medicine, Inc. (NASDAQ:FMI) insider Vincent A. Miller sold 2,944 shares of Foundation Medicine stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $38.80, for a total value of $114,227.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Foundation Medicine, Inc. (FMI) opened at 44.70 on Friday. The company has a 50-day moving average of $39.45 and a 200 day moving average of $37.35. The firm’s market cap is $1.61 billion. Foundation Medicine, Inc. has a 52 week low of $17.10 and a 52 week high of $44.95.

Foundation Medicine (NASDAQ:FMI) last announced its earnings results on Tuesday, August 1st. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.16). Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The company had revenue of $35.00 million for the quarter, compared to analysts’ expectations of $34.94 million. During the same period in the prior year, the company earned ($0.84) earnings per share. The company’s revenue for the quarter was up 23.9% on a year-over-year basis. On average, equities analysts predict that Foundation Medicine, Inc. will post ($4.67) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Vincent A. Miller Sells 2,944 Shares of Foundation Medicine, Inc. (FMI) Stock” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/vincent-a-miller-sells-2944-shares-of-foundation-medicine-inc-fmi-stock/1612511.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC lifted its holdings in shares of Foundation Medicine by 12.4% during the fourth quarter. Teachers Advisors LLC now owns 23,071 shares of the company’s stock valued at $408,000 after purchasing an additional 2,538 shares during the last quarter. Adalta Capital Management LLC purchased a new stake in shares of Foundation Medicine during the first quarter valued at $4,056,000. Cannell Peter B & Co. Inc. purchased a new stake in shares of Foundation Medicine during the second quarter valued at $1,093,000. Whittier Trust Co. lifted its holdings in shares of Foundation Medicine by 3.1% during the second quarter. Whittier Trust Co. now owns 43,338 shares of the company’s stock valued at $1,723,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Foundation Medicine by 1.3% during the second quarter. Oppenheimer & Co. Inc. now owns 684,090 shares of the company’s stock valued at $27,192,000 after purchasing an additional 9,050 shares during the last quarter. 31.84% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently weighed in on the stock. BidaskClub downgraded shares of Foundation Medicine from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Zacks Investment Research downgraded shares of Foundation Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $35.00.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.